Showing 4121-4130 of 5646 results for "".
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001https://modernod.com/news/frontera-therapeutics-receives-additional-ind-clearance-for-its-lead-program-ft-001/2481106/Frontera Therapeutics announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE), NMPA, in China. The FDA also cleared an IND for
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Irelandhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-ireland/2481105/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segme
- European Commission Approves Roche’s Vabysmo for Wet AMD and DMEhttps://modernod.com/news/european-commission-approves-roches-vabysmo-for-wet-amd-and-dme/2481102/Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME). “Many people with nAMD and DME struggle to keep up with the mont
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study
- Glaukos Announces Positive Topline Outcomes in Two Phase 3 Pivotal Trials of iDose TRhttps://modernod.com/news/glaukos-announces-positive-topline-outcomes-for-both-phase-3-pivotal-trials-of-idose-tr/2481092/Glaukos announced positive topline data for both phase 3 pivotal trials of iDose TR that successfully achieved its prespecified primary efficacy endpoints through 3 months in both phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 1
- Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on AMDhttps://modernod.com/news/bausch-lomb-sponsored-visionary-report-spotlights-nations-blind-spots-on-amd/2481091/Bausch + Lomb released a report of survey results from the company’s first Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and aware
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named